News | October 08, 2024
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
CSPC will receive an upfront payment of $100 million from AstraZeneca
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
The inspection concluded with the issuance of a form 483 with five observations
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Subscribe To Our Newsletter & Stay Updated
